RT Journal Article
SR Electronic
T1 Performance of Gazelle COVID-19 point-of-care test for detection of nucleocapsid antigen from SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.23.22272094
DO 10.1101/2022.03.23.22272094
A1 Mehta, Amrish
A1 Spencer, Bri
A1 Garg, Ashok
A1 Kalmorge, Pradeep
A1 Ocasio Gonzalez, Raúl A.
A1 Taussig, Kate
A1 Fortna, Ryan R.
YR 2022
UL http://medrxiv.org/content/early/2022/03/23/2022.03.23.22272094.abstract
AB SARS-CoV-2 antigen assays offer simplicity and rapidity in diagnosing COVID-19. We assessed the clinical performance of Gazelle COVID-19 test, a fluorescent lateral flow immunoassay with an accompanying Reader utilizing image-recognition software for detection of nucleocapsid antigen from SARS-CoV-2. We performed a prospective, operator-blinded, observational study at 2 point-of-care (POC) sites. Nasal swab specimens from symptomatic patients were tested with Gazelle COVID-19 test and real-time polymerase chain reaction (RT-P CR) assay. Overall, data from 1524 subjects was analyzed, and 133 were positive by RT-PCR. Mean (range) age of participants was 34.7 (2-94) years and 570 (37.4%) were female. The sensitivity and the specificity of the Gazelle COVID-19 test were 96.3% and 99.7%. The PPV of Gazelle COVID-19 test was 97.0%, NPV 99.6%, and accuracy 99.4%. In POC settings, Gazelle COVID-19 test had high diagnostic accuracy for detection of SARS-CoV-2 in nasal swab samples of symptomatic subjects suspected of COVID-19.Competing Interest StatementROG and KT were hired as consultants by Hemex Health to execute this study. AM is a board member of HemexDx, a subsidiary of Hemex Health in India.Clinical TrialNCT04987918Funding StatementThe funding for the study was provided by Hemex Health, Inc., USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approval was obtained by the sponsor before starting the study in the United States (WCG IRB Tracking number: 20212857). Study protocol from India was approved by the Ethics Committee of International Institute of Sleep Sciences (Reg No: ECR/177/Indt/MH-2014/RR-19). Informed consents were obtained from all study participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.